Large B-Cell Lymphoma (LBCL)
Oncology·MeSH: Lymphoma, Non-Hodgkin
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| cema-cel | Allogene Therapeutics, Inc. (ALLO) |
Frequently asked questions
How many drugs are in development for Large B-Cell Lymphoma (LBCL)?
BioSniper tracks 1 drug in development for Large B-Cell Lymphoma (LBCL) across 1 company.
How many clinical trials target Large B-Cell Lymphoma (LBCL)?
There are 1 clinical trial targeting Large B-Cell Lymphoma (LBCL) tracked by BioSniper.
What is the prevalence of Large B-Cell Lymphoma (LBCL)?
The estimated prevalence of Large B-Cell Lymphoma (LBCL) is approximately 30.0 per 100,000 population.
Deep-dive into Large B-Cell Lymphoma (LBCL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis